Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Oct 14, 2024 7:51pm
186 Views
Post# 36265688

5 Turkish Sites Dosing

5 Turkish Sites DosingAt some point and time the markets will finally wake up and realize that Arch has been dosing at 5 sites for almost 8 months. We have no idea how many patients have been dosed but we know that there has been zero adverse reactions to the dosing. This is huge positive fact.

The other huge factor is they are dosing at 4x times  the previous phase 2 dosage, this could produce stellar results.

IMO they have most likely dosed 100+ patients.

Daily volume continues to struggle and now is the time for management to step up and start promoting the story. Management needs to start pounding the payment, spend some $$$ promoting this opportunity and drive new buyers to the market.

There are many aspects out of the  control of management but promoting the story is in their control and is their responsibility!

Good luck to all the longs!!
<< Previous
Bullboard Posts
Next >>